Frankfurt - Delayed Quote EUR

Nyxoah SA (5YI.F)

5.18

-0.01

(-0.19%)

At close: May 2 at 3:29:02 PM GMT+2

Conditional Issuance of Shares

INSIDE INFORMATIONREGULATED INFORMATION Conditional Issuance of Shares Mont-Saint-Guibert, Belgium – April 16, 2025, 8:00 am CET / 2:00 am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), today announced a conditional issuance of up to 5 million ordinary shares under its existing at-the-market equity offering programs (the “ATM”). This brings the aggregate number of ordinary shares that can be sold and issued under the Company’s ATM to 5,662,694 (the “ATM Shares”), wh

GlobeNewswire 18 days ago

NYXH
Nyxoah Provides Update on FDA Approvable Letter for Genio System

Nyxoah Provides Update on FDA Approvable Letter for Genio System Expects to meet final FDA requirements for full PMA approval in the second quarter Mont-Saint-Guibert, Belgium – April 8, 2025, 07:00am CET / 1:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), which develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced an update on the FDA approval process for the Genio system. On March 26, 2025, the

GlobeNewswire 26 days ago

NYXH
FDA Issues Nyxoah an Approvable Letter for its Genio® System

INSIDE INFORMATIONREGULATED INFORMATION FDA Issues Nyxoah an Approvable Letter for its Genio® System Mont-Saint-Guibert, Belgium – March 26, 2025, 8:00am CET / 3:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the U.S. Food and Drug Administration (FDA) has issued an Approvable Letter regarding the Company's Pre-Market Approval (PMA)

GlobeNewswire last month

NYXH
Nyxoah SA (NYXH) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic US ...

Nyxoah SA (NYXH) reports significant revenue growth and outlines strategic plans for US market entry, despite increased operating losses.

GuruFocus.com last month

NYXH.BR
Nyxoah SA (NYXH) Reports Q4 Loss, Lags Revenue Estimates

Nyxoah (NYXH) delivered earnings and revenue surprises of 2% and 40.19%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

NYXH.BR
Nyxoah Reports Fourth Quarter and Financial Year 2024 Financial and Operating Results

REGULATED INFORMATION Nyxoah Reports Fourth Quarter and Financial Year 2024 Financial and Operating ResultsFDA PMA Application Review Nearing ConclusionPositioned for U.S. Commercial Launch in March 2025 Mont-Saint-Guibert, Belgium – March 13, 2024, 7:00am CET / 2:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported financial and operating resul

GlobeNewswire last month

NYXH
Nyxoah to Release Fourth Quarter and Financial Year 2024 Financial Results on March 13, 2025

Nyxoah to Release Fourth Quarter and Financial Year 2024 Financial Results on March 13, 2025 Mont-Saint-Guibert, Belgium – Monday, March 10, 2025, 10:05pm CET / 5:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the fourth quarter and financial year 2024 on Thursday, March 13, 2025. Compan

GlobeNewswire last month

NYXH
Nyxoah to Participate in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference

Nyxoah to Participate in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference Mont-Saint-Guibert, Belgium – March 3, 2025, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will participate in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference, which takes place March 17 – 20

GlobeNewswire last month

NYXH
Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Middle East

Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Middle EastFirst patient implanted with Genio at Saudi German Hospital in Dubai, United Arab Emirates Mont-Saint-Guibert, Belgium – February 19, 2025, 7:05am CET / 1:05am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced the commercial launch of

GlobeNewswire 2 months ago

NYXH
Hims & Hers Health (HIMS) Surges 27.7%: Is This an Indication of Further Gains?

Hims & Hers Health (HIMS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks 2 months ago

NYXH.BR
Publication relating to transparency notifications

REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), January 20, 2025, 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. BlackRock, Inc. On January 16, 2025, Nyxoah received a transparency notification from BlackRock, Inc. and related persons. Based on the n

GlobeNewswire 3 months ago

NYXH
Nyxoah introduces neurostimulator device for sleep apnoea in England

The battery-free, single-incision, and leadless system represents a solution for adults suffering from moderate to severe OSA.

Medical Device Network 4 months ago

NYXH.BR
Tongue Implant Could Treat Sleep Apnea Without a CPAP

It uses neurostimulation to keep the tongue from sliding back and blocking the airway.

Design & Development Today 4 months ago

NYXH.BR
Nyxoah Announces Commercial Launch of Genio® Innovative Therapy in England

Nyxoah Announces Commercial Launch of Genio® Innovative Therapy in EnglandFirst patients implanted with Genio at UCLH, London Mont-Saint-Guibert, Belgium – December 13, 2024, 8:05am CET / 2:05am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced the commercial launch of its Genio system in England, marked by the first

GlobeNewswire 4 months ago

NYXH
Information on the total number of voting rights and shares

REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), November 27, 2024, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares. Share capital: EUR 6,429,682.56 Total number of securities carrying voting rights: 37,427,265 (all ordinary shares) Total number o

GlobeNewswire 5 months ago

NYXH
Nyxoah to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nyxoah to Participate in the Piper Sandler 36th Annual Healthcare Conference Mont-Saint-Guibert, Belgium – November 20, 2024, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will participate in the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024. T

GlobeNewswire 5 months ago

NYXH
Invitation to attend the special shareholders’ meeting of the Company to be held on December 19, 2024

REGULATED INFORMATIONNovember 19, 2024, 7:00am CET / 1:00am ET NYXOAH SA(Euronext Brussels/Nasdaq: NYXH) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium(hereinafter the “Company”) Invitation to attend the special shareholders’ meeting of the Company to be held on December 19, 2024 The board of directors of the Company is pleased to invite its securities holders to attend the special shareholders' meeting of the Company, to be held on Thursday, December 19, 2024 at 3:00 p.m. CET at the Com

GlobeNewswire 5 months ago

NYXH
Nyxoah SA (NYXH) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

Nyxoah SA (NYXH) strengthens its financial position and prepares for US market entry despite increased operating losses and delayed FDA approval.

GuruFocus.com 5 months ago

NYXH.BR
Nyxoah SA (NYXH) Reports Q3 Loss, Tops Revenue Estimates

Nyxoah (NYXH) delivered earnings and revenue surprises of -47.83% and 17.72%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 5 months ago

NYXH.BR
Nyxoah Reports Third Quarter Financial and Operating Results

REGULATED INFORMATION Nyxoah Reports Third Quarter Financial and Operating ResultsFDA approval on track for first quarter 2025, U.S. commercial team build out in progressCompany fully funded with cash until mid 2026 Mont-Saint-Guibert, Belgium – November 6, 2024, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation,

GlobeNewswire 5 months ago

NYXH

Performance Overview

Return	5YI.F	BEL 20 (^BFX)
YTD	-32.20%	+6.33%
1-Year	-41.00%	+15.41%
3-Year	-66.58%	+10.71%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Nyxoah SA (5YI.F)

Conditional Issuance of Shares

Nyxoah Provides Update on FDA Approvable Letter for Genio System

FDA Issues Nyxoah an Approvable Letter for its Genio® System

Nyxoah SA (NYXH) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic US ...

Nyxoah SA (NYXH) Reports Q4 Loss, Lags Revenue Estimates

Nyxoah Reports Fourth Quarter and Financial Year 2024 Financial and Operating Results

Nyxoah to Release Fourth Quarter and Financial Year 2024 Financial Results on March 13, 2025

Nyxoah to Participate in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference

Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Middle East

Hims & Hers Health (HIMS) Surges 27.7%: Is This an Indication of Further Gains?

Publication relating to transparency notifications

Nyxoah introduces neurostimulator device for sleep apnoea in England

Tongue Implant Could Treat Sleep Apnea Without a CPAP

Nyxoah Announces Commercial Launch of Genio® Innovative Therapy in England

Information on the total number of voting rights and shares

Nyxoah to Participate in the Piper Sandler 36th Annual Healthcare Conference

Invitation to attend the special shareholders’ meeting of the Company to be held on December 19, 2024

Nyxoah SA (NYXH) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

Nyxoah SA (NYXH) Reports Q3 Loss, Tops Revenue Estimates

Nyxoah Reports Third Quarter Financial and Operating Results

Performance Overview